Hepatocyte senescence in end-stage chronic liver disease: A study of cyclin-dependent kinase inhibitor p21 in liver biopsies as a marker for progression to hepatocellular carcinoma

Liver International

Volumn 27, Issue 5, 2007, Pages 662-671

  Brunt, Elizabeth M ^a,b   Walsh, Sarah N ^a   Hayashi, Paul H ^a,b   Labundy, Jennifer ^a   Di Bisceglie, Adrian M ^a,b  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Saint Louis University   (United States)

Author keywords

Chronic liver disease; Hepatocellular carcinoma; Senescense

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1A; IRON; KI 67 ANTIGEN; TUMOR MARKER;

ADULT; ARTICLE; CELL CYCLE; CELL PROLIFERATION; CELL STRUCTURE; CHRONIC LIVER DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION COEFFICIENT; CRITERION VARIABLE; DISEASE COURSE; DYSPLASIA; FATTY LIVER; FEMALE; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER BIOPSY; LIVER CELL; LIVER CELL CARCINOMA; LIVER FIBROSIS; LIVER NECROSIS; LIVER TRANSPLANTATION; MALE; SENESCENCE; STANDARD;

ADULT; APOPTOSIS; BIOPSY; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DISEASE PROGRESSION; FEMALE; HEPATOCYTES; HUMANS; IMMUNOHISTOCHEMISTRY; KERATIN-7; KI-67 ANTIGEN; LIVER; LIVER NEOPLASMS; MALE; MIDDLE AGED; TUMOR MARKERS, BIOLOGICAL;

EID: 34547096243     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2007.01470.x     Document Type: Article

References (24)

1. Thorgeirsson SS, Grisham JW. Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet 2002; 31: 339-46.
2. Roberts LR, Gores GJ. Hepatocellular carcinoma: Molecular pathways and new therapeutic targets. Semin Liv Dis 2005; 25: 212-25.
3. Befeler AS, Di Bisceglie AM. Hepatocellular carcinoma: Diagnosis and treatment. Gastroenterology 2002; 122: 1609-19.
4. El-Serag HB. Hepatocellular carcinoma: Recent trends in the Unites States. Gastroenterology 2004; 127: S27-34.
5. Sherman M. Hepatocellular carcinoma: Epidemiology, risk factors and screening. Semin Liv Dis 2005; 25: 143-54.
6. Kobayashi M, Ikeda K, Hosaka T, et al. Dysplastic nodules frequently develop into hepatocellular carcinoma in patients with chronic viral hepatitis and cirrhosis. Cancer 2006; 106: 636-47.
7. Kojiro M, Roskams T. Early hepatocellular carcinoma and dysplastic nodules. Semin Liv Dis 2005; 25: 133-42.
8. Paradis V, Youssef N, Dargere D, et al. Replicative senescence in normal liver, chronic hepatitis C, and hepatocellular carcinomas. Hum Pathol 2001; 32: 327-32.
9. Lunz JG, Tsuji H, Nozaki I, Murase N, Demetris AJ. An inhibitor of cyclin-dependent kinase, stress-induced p21 Waf-1/Cip-1, mediates hepatocyte mito-inhibition during the evolution of cirrhosis. Hepatology 2005; 41: 1262-71.
10. Wagayama H, Shiraki K, Yamanaka T, et al. p21 WAF1/CIP1 expression and hepatitis virus type. Dig Dis Sci 2001; 46: 2074-9.
11. Wiemann SU, Satyanarayana A, Tsahuridu M, et al. Hepatocyte telomere shortening and senescence are general markers of human liver cirrhosis. FASEB J 2002; 16: 935-42.
12. Marshall A, Rushbrook S, Davies SE, et al. Relation between hepatocyte G1 arrest, impaired hepatic regeneration, and fibrosis in chronic hepatitis C virus infection. Gastroenterology 2005; 128: 33-42.
13. Clouston AD, Powell EE, Walsh MJ, Richardson MM, Demetris AJ, Jonsson JR. Fibrosis correlates with a ductular reaction in hepatitis C: Roles of impaired replication, progenitor cells and steatosis. Hepatology 2005; 41: 809-18.
14. Hui A-M, Kanai Y, Sakamoto M, Tsuda H, Hirohashi S. Reduced p21 WAF1/ CIP1 expression and p53 mutation in hepatocellular carcinomas. Hepatology 1997; 25: 575-9.
15. Crary GS, Albrecht JH. Expression of cyclin-dependent kinase inhibitor p21 in human liver. Hepatology 1998; 28: 738-43.
16. Roskams TA, Theise ND, Balabaud C, et al. Nomenclature of the finer branches of the biliary tree: Canals, ductules and ductular reactions in human livers. Hepatology 2004; 39: 1739-45.
17. Eleazar JA, Memeo L, Jhang JS, et al. Progenitor cell expansion: An important source of hepatocyte regeneration in chronic hepatitis. J Hepatol 2004; 41: 983-91.
18. Ishak KG, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696-9.
19. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histologic scoring system for nonalcoholic fatty liver disease. Hepatology 2004; 41: 1313-20.
20. Kofman AV, Morgan G, Kirschenbaum A, et al. Dose- and time-dependent oval cell reaction in acetoaminophen-induced murine liver injury. Hepatology 2005; 41: 1252-61.
21. Bialecki ES, Ezenekwe AM, Brunt EM, et al. Comparison of liver biopsy and noninvasive methods for diagnosis of hepatocellular carcinoma. Clin Gastroenterol Hepatol 2006; 4: 361-8.
22. Libbrecht L, Desmet V, Roskams T. Preneoplastic lesions in human hepatocarcinogenesis. Liver Int 2005; 25: 16-27.
23. Quaglia A, Jutand MA, Dhillon A, et al. Classification tool for the systematic histological assessment of hepatocellular carcinoma, macroregenerative nodules, and dysplastic nodules in cirrhotic liver. World J Gastroenterol 2005; 11: 6262-8.
24. Marrero JA, Fontana RJ, Su GL, Conjeevaram HS, Emick DM, Lok AS. NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology 2002; 36: 1349-54.